Nineteen biotechs raised $972.7 million via IPOs in 2011, including five companies last quarter. This compares to 31 IPOs that raised $1.6 billion in 2010. The 2011 class traded down a median of 19%, with 13 of 19 companies ending the year below their post-money valuation. The market values for traditional Chinese medicines company Tibet Pharmaceuticals Inc. (NASDAQ:TBET), small